Ovid Therapeutics Inc (OVID) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.69 (-0.37%), Market cap $0.53B, 52-week low–high $0.27 ~ $2.96.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern Un
Financial statements, price targets, institutional (13F) holdings and related news for Ovid Therapeutics Inc are updated in real time on BlackAll Trade.
Ovid Therapeutics Inc trades at $2.69 (-0.37%). Real-time quotes and charts are available on BlackAll Trade.
Ovid Therapeutics Inc has a market cap of about $0.53B.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the U